These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26325094)

  • 21. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
    van den Buuse M; Gogos A
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.
    Ye N; Song Z; Zhang A
    Curr Med Chem; 2014; 21(4):437-57. PubMed ID: 24164194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Descending modulation of neuropathic hypersensitivity by dopamine D2 receptors in or adjacent to the hypothalamic A11 cell group.
    Wei H; Viisanen H; Pertovaara A
    Pharmacol Res; 2009 May; 59(5):355-63. PubMed ID: 19416636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
    Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
    Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors.
    Ueda T; Ugawa S; Ishida Y; Shimada S
    Eur J Pharmacol; 2011 Dec; 671(1-3):79-86. PubMed ID: 21951966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
    Li Z; Huang J; Sun H; Zhou S; Guo L; Zhou Y; Zhen X; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):5838-46. PubMed ID: 25308766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of chloride channel coupled GABA(C) receptors in the peripheral antinociceptive effect induced by GABA(C) receptor agonist cis-4-aminocrotonic acid.
    Reis GM; Duarte ID
    Life Sci; 2007 Mar; 80(14):1268-73. PubMed ID: 17316706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
    Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
    Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Endocannabinoid System in the Peripheral Antinociceptive Action of Aripiprazole.
    Ferreira RCM; Almeida-Santos AF; Duarte IDG; Aguiar DC; Moreira FA; Romero TRL
    Anesth Analg; 2019 Jul; 129(1):263-268. PubMed ID: 30198932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms underlying the antinociceptive effect of mangiferin in the formalin test.
    Izquierdo T; Espinosa de los Monteros-Zuñiga A; Cervantes-Durán C; Lozada MC; Godínez-Chaparro B
    Eur J Pharmacol; 2013 Oct; 718(1-3):393-400. PubMed ID: 23973647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies.
    Łukasiewicz S; Błasiak E; Szafran-Pilch K; Dziedzicka-Wasylewska M
    J Neurochem; 2016 May; 137(4):549-60. PubMed ID: 26876117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.